# Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer

> **NCT05152797** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 91 (estimated)

## Conditions studied

- Tumor Infiltrating Lymphocytes

## Interventions

- **BIOLOGICAL:** Autologous tumor-infiltrating lymphocytes

## Key facts

- **NCT ID:** NCT05152797
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2021-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152797, "Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05152797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*